Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc (MRNS)

$3.21
-0.25 (-7.23%)
Neutral
Symbol MRNS
Price 3.21$
Beta 1.531
Volume Avrg. 4.78M
Market Cap 0.39B
Shares (2019) 54,512.78K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -90.85% Strong Sell
ROA -54.76% Strong Sell
Operating Margin -Infinity% Strong Sell
Debt / Equity 65.93% Buy
P/E -2.12 Sell
P/B 1.92 Strong Buy

Retained Earning Schedule

Year 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) --56-62-72-97-126-145-181
Net Income ---11-25-29-19-37-54
Stock Dividends -56-5-0-----
Dividend Paid --------
Retained Earnings -56-62-72-97-126-145-181-236

PPE Schedule

Year 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE -0000111
Annual Depreciation 000-02104
Capital Expenditure -0-0-0--1-0-0-0
Net PPE 00001115

Intangible and Goodwill Schedule

Year 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) --------
New Purchases ----8-2-25--3
Intangible and Goodwill --------

About


Dr. Scott Braunstein
Healthcare
Biotechnology
NASDAQ Global Market

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 41 full-time employees. The firm focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The firm is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.